JP6298449B2 - 超音波接触流動体 - Google Patents
超音波接触流動体 Download PDFInfo
- Publication number
- JP6298449B2 JP6298449B2 JP2015510813A JP2015510813A JP6298449B2 JP 6298449 B2 JP6298449 B2 JP 6298449B2 JP 2015510813 A JP2015510813 A JP 2015510813A JP 2015510813 A JP2015510813 A JP 2015510813A JP 6298449 B2 JP6298449 B2 JP 6298449B2
- Authority
- JP
- Japan
- Prior art keywords
- contact fluid
- composition
- fluid according
- amount
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000012530 fluid Substances 0.000 title claims description 72
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- 238000012285 ultrasound imaging Methods 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 239000003995 emulsifying agent Substances 0.000 claims description 11
- 239000003906 humectant Substances 0.000 claims description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 6
- 239000003921 oil Substances 0.000 claims description 5
- 235000019198 oils Nutrition 0.000 claims description 5
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 4
- 239000003925 fat Substances 0.000 claims description 4
- 235000019197 fats Nutrition 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000787 lecithin Substances 0.000 claims description 4
- 235000010445 lecithin Nutrition 0.000 claims description 4
- 229940067606 lecithin Drugs 0.000 claims description 4
- 239000002504 physiological saline solution Substances 0.000 claims description 4
- 239000003549 soybean oil Substances 0.000 claims description 4
- 235000012424 soybean oil Nutrition 0.000 claims description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 4
- 239000008158 vegetable oil Substances 0.000 claims description 4
- 238000013016 damping Methods 0.000 claims description 3
- 229920005862 polyol Polymers 0.000 claims description 3
- 150000003077 polyols Chemical class 0.000 claims description 3
- 150000003626 triacylglycerols Chemical class 0.000 claims description 3
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 claims description 2
- 241000251468 Actinopterygii Species 0.000 claims description 2
- 244000060011 Cocos nucifera Species 0.000 claims description 2
- 235000013162 Cocos nucifera Nutrition 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 2
- 229940081733 cetearyl alcohol Drugs 0.000 claims description 2
- 239000003240 coconut oil Substances 0.000 claims description 2
- 235000019864 coconut oil Nutrition 0.000 claims description 2
- 235000019688 fish Nutrition 0.000 claims description 2
- 235000021323 fish oil Nutrition 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 235000021243 milk fat Nutrition 0.000 claims description 2
- 239000004006 olive oil Substances 0.000 claims description 2
- 235000008390 olive oil Nutrition 0.000 claims description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
- 229940068977 polysorbate 20 Drugs 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims 1
- 235000019737 Animal fat Nutrition 0.000 claims 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims 1
- 229940083466 soybean lecithin Drugs 0.000 claims 1
- 238000002604 ultrasonography Methods 0.000 description 25
- 210000001519 tissue Anatomy 0.000 description 17
- 238000001356 surgical procedure Methods 0.000 description 16
- 210000004556 brain Anatomy 0.000 description 12
- 239000000499 gel Substances 0.000 description 11
- 230000008878 coupling Effects 0.000 description 10
- 238000010168 coupling process Methods 0.000 description 10
- 238000005859 coupling reaction Methods 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 239000000523 sample Substances 0.000 description 8
- 238000003384 imaging method Methods 0.000 description 7
- 238000002679 ablation Methods 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 208000003174 Brain Neoplasms Diseases 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 230000001902 propagating effect Effects 0.000 description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 239000007822 coupling agent Substances 0.000 description 3
- -1 fatty acid esters Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000007660 Residual Neoplasm Diseases 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 2
- 238000007598 dipping method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000010687 lubricating oil Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000008385 outer phase Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 210000001154 skull base Anatomy 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000002330 subarachnoid space Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/226—Solutes, emulsions, suspensions, dispersions, semi-solid forms, e.g. hydrogels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/42—Details of probe positioning or probe attachment to the patient
- A61B8/4272—Details of probe positioning or probe attachment to the patient involving the acoustic interface between the transducer and the tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/08—Detecting organic movements or changes, e.g. tumours, cysts, swellings
- A61B8/0808—Detecting organic movements or changes, e.g. tumours, cysts, swellings for diagnosis of the brain
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Acoustics & Sound (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Surgical Instruments (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Description
減衰量[dB]=α[dB/(MHz*cm)*l[cm]*f[MHz]
ここで、αは減衰係数であり、lは媒体長(すなわち、伝播距離)であり、fは伝達される超音波の周波数である。
模型において、針をオアシスとされた腔内に挿入し、平型線形アレイ(Vingmed Ultrasound System FiVe)によって映像化した。画像は、図2における左(A)に示される正規の生理食塩水でなされ、図2における右(B)で示される高い減衰量を持つ本発明による接触流動体でなされた。同じ取得パラメータが使用されたが、全体のゲインは、熟練した超音波オペレータによって規定されるような「最良の画像」を提供するために、各々のケースにおいて調整された。(A)における腔の底部の下の明るい領域は、ほとんど、(B)において完全に消滅されている。従って、本発明による減衰量を持つ接触流動体を使用してなされた画像は、(A)において存在するアーティファクトなしで、より正確な映像を与える。
新たに殺した子豚を、生理食塩水又は本発明による接触流動体を使用して画像化品質を比較するために実験に使用した。新鮮な子豚脳においてなされた切除腔(図3における矢印でマークされている)を、(a)切除腔を生理的塩類溶液を使用して画像化し、(b)本発明による接触流動体を使用して画像化した。取得パラメータは、両方のケースにおいて同じである。画像のより深い部分での主流の信号増大は、スカルベースからの強い反射によって引き起こされる。2つの画像(aおよびb)における切除腔の下の強度の差は、顕著である。たとえスライス方向が画像において完全に同一でないとしても、bにおいて切除腔の底部の真下に擬似信号増大がないことは明らかである。信号強度の差は、また、aおよびbにおいて、より深い骨反射においても見られる。
Claims (12)
- 医薬品グレードのトリグリセリドと、医薬的に許容な乳化剤と、選択的に医薬的に許容な保湿剤と、を有する組成物である接触流動体であって、該接触流動体は、超音波イメージングにおける水溶性超音波接触流動体として使用されるものであり、前記トリグリセリド含有率は、8〜240g/1000ml組成物の範囲にあり、乳化剤の量は、0.4〜18g/1000ml組成物であり、選択的に、保湿剤の量は、1.2〜30g/1000ml組成物である、接触流動体。
- トリグリセリドの量は、10〜200g/1000ml組成物の範囲にあり、乳化剤の量は、0.5〜15g/1000ml組成物であり、選択的に、保湿剤の量は、1.2〜25g/1000ml組成物である、請求項1に記載の接触流動体。
- トリグリセリドの量は、50〜110g/1000ml組成物であり、乳化剤の量は、2〜10g/1000ml組成物であり、選択的に、保湿剤の量は、5〜15g/1000ml組成物である、請求項1に記載の接触流動体。
- 前記トリグリセリドは、植物性油又は動物性脂肪から選択される、請求項1乃至3のいずれか1つに記載の接触流動体。
- 前記植物性油又は動物性脂肪は、大豆油、オリーブ油、ヤシ油、コプラ油、乳脂肪、魚油、および魚レバー油のグループから選択される、請求項4に記載の接触流動体。
- 前記乳化剤は、レシチン、卵黄レシチン、大豆レシチン、乳状蝋、セテアリルアルコール、ポリソルベイト20、およびセテアレス20のグループから選択される、請求項1乃至5のいずれか1つに記載の接触流動体。
- 前記保湿剤は、グリセロール、乳酸、ポリオール、プロピレングリコール、およびソルビトールのグループから選択される、請求項1乃至6のいずれか1つに記載の接触流動体。
- pH調整添加剤を有する、請求項1乃至7のいずれか1つに記載の接触流動体。
- 前記pH調整添加剤は、pHが6〜8の範囲に、好ましくは、7に設定される量で加えられる請求項8に記載の接触流動体。
- 1000mlの接触流動体を得るために、90gの大豆油、5.5gのレシチン、および10gのグリセロールと、生理的塩水とを有する、請求項1乃至9のいずれか1つに記載の接触流動体。
- 減衰係数α>0.066を持つ、請求項1乃至10のいずれか1つに記載の接触流動体。
- 0.20〜1.10の範囲、好ましくは、約0.80の減衰係数を持つ請求項11に記載の接触流動体。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NO20120529 | 2012-05-09 | ||
NO20120529 | 2012-05-09 | ||
PCT/EP2013/059588 WO2013167654A1 (en) | 2012-05-09 | 2013-05-08 | Ultrasound contact fluid |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015522530A JP2015522530A (ja) | 2015-08-06 |
JP6298449B2 true JP6298449B2 (ja) | 2018-03-20 |
Family
ID=48326313
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015510813A Active JP6298449B2 (ja) | 2012-05-09 | 2013-05-08 | 超音波接触流動体 |
Country Status (10)
Country | Link |
---|---|
US (1) | US9770521B2 (ja) |
EP (1) | EP2846841B1 (ja) |
JP (1) | JP6298449B2 (ja) |
CN (1) | CN104334197B (ja) |
AU (1) | AU2013258028B2 (ja) |
CA (1) | CA2872142C (ja) |
DK (1) | DK2846841T3 (ja) |
ES (1) | ES2616059T3 (ja) |
IN (1) | IN2014DN09246A (ja) |
WO (1) | WO2013167654A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6954923B2 (ja) * | 2016-01-10 | 2021-10-27 | スマイルソニカ・インコーポレイテッドSmileSonica Inc. | 粘度および安定性が改善された超音波ゲル |
US11478435B2 (en) | 2017-02-22 | 2022-10-25 | Smilesonica Inc. | Artificial saliva, related methods, and uses |
GB202116863D0 (en) | 2021-11-23 | 2022-01-05 | Sonoclear As | Ultrasound coupling agent |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4542745A (en) | 1983-06-27 | 1985-09-24 | Technicare Corporation | Ultrasonic emulsion fluids |
US5644429A (en) * | 1992-07-23 | 1997-07-01 | Research Foundation Of City College Of New York | 2-dimensional imaging of translucent objects in turbid media |
GB9305349D0 (en) | 1993-03-16 | 1993-05-05 | Nycomed Imaging As | Improvements in or relating to contrast agents |
DE4328642A1 (de) * | 1993-08-26 | 1995-03-02 | Byk Gulden Lomberg Chem Fab | Ultraschallkontrastmittel |
US5625137A (en) | 1995-05-25 | 1997-04-29 | Wisconsin Alumni Research Foundation | Very low scatter liquid and solid tissue mimicking material for ultrasound phantoms and method of making the same |
US6302848B1 (en) | 1999-07-01 | 2001-10-16 | Sonotech, Inc. | In vivo biocompatible acoustic coupling media |
US6475800B1 (en) | 1999-07-22 | 2002-11-05 | Instrumentation Metrics, Inc. | Intra-serum and intra-gel for modeling human skin tissue |
US20050074407A1 (en) | 2003-10-01 | 2005-04-07 | Sonotech, Inc. | PVP and PVA as in vivo biocompatible acoustic coupling medium |
US20060127316A1 (en) | 2004-12-14 | 2006-06-15 | Sonotech, Inc. | Polyols and PVP as in vivo biocompatible acoustic coupling media |
CN100427142C (zh) * | 2005-01-10 | 2008-10-22 | 重庆海扶(Hifu)技术有限公司 | 一种高强度聚焦超声治疗用助剂及其筛选方法 |
CN100574811C (zh) * | 2005-01-10 | 2009-12-30 | 重庆海扶(Hifu)技术有限公司 | 一种高强度聚焦超声治疗用微粒类助剂及其应用 |
EP2152167B1 (en) | 2007-05-07 | 2018-09-05 | Guided Therapy Systems, L.L.C. | Methods and systems for coupling and focusing acoustic energy using a coupler member |
WO2009013692A2 (en) | 2007-07-25 | 2009-01-29 | Koninklijke Philips Electronics N.V. | Multimodality matching medium for diffuse optical tomography and ultrasound measurements |
CN101695576A (zh) | 2009-10-21 | 2010-04-21 | 新余市博源生化医用品有限责任公司 | 医用超声杀菌型藕合剂 |
-
2013
- 2013-05-08 CA CA2872142A patent/CA2872142C/en active Active
- 2013-05-08 DK DK13721347.6T patent/DK2846841T3/en active
- 2013-05-08 ES ES13721347.6T patent/ES2616059T3/es active Active
- 2013-05-08 AU AU2013258028A patent/AU2013258028B2/en active Active
- 2013-05-08 JP JP2015510813A patent/JP6298449B2/ja active Active
- 2013-05-08 CN CN201380023614.5A patent/CN104334197B/zh active Active
- 2013-05-08 EP EP13721347.6A patent/EP2846841B1/en active Active
- 2013-05-08 IN IN9246DEN2014 patent/IN2014DN09246A/en unknown
- 2013-05-08 US US14/398,871 patent/US9770521B2/en active Active
- 2013-05-08 WO PCT/EP2013/059588 patent/WO2013167654A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2013167654A1 (en) | 2013-11-14 |
ES2616059T3 (es) | 2017-06-09 |
DK2846841T3 (en) | 2017-02-27 |
JP2015522530A (ja) | 2015-08-06 |
AU2013258028A1 (en) | 2014-12-04 |
CA2872142C (en) | 2021-01-05 |
AU2013258028B2 (en) | 2018-06-14 |
CA2872142A1 (en) | 2013-11-14 |
US20150118161A1 (en) | 2015-04-30 |
CN104334197A (zh) | 2015-02-04 |
IN2014DN09246A (ja) | 2015-07-10 |
US9770521B2 (en) | 2017-09-26 |
CN104334197B (zh) | 2017-03-15 |
EP2846841B1 (en) | 2016-11-23 |
EP2846841A1 (en) | 2015-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Fahey et al. | Acoustic radiation force impulse imaging of thermally-and chemically-induced lesions in soft tissues: preliminary ex vivo results | |
US8043604B2 (en) | Ultrasonography using time- and temperature-sensitive variable adhesion coupling gels | |
Nguyen et al. | Monitoring of cornea elastic properties changes during UV-A/riboflavin-induced corneal collagen cross-linking using supersonic shear wave imaging: a pilot study | |
Dennis | Use of magnetic resonance imaging for the investigation of orbital disease in small animals | |
Ukimura et al. | Real-time transrectal ultrasonography during laparoscopic radical prostatectomy | |
Squarzoni et al. | Ultrasonographic aspects and biometry of Striped owl’s eyes (Rhinoptynx clamator) | |
Zhang et al. | Dynamic changes of integrated backscatter, attenuation coefficient and bubble activities during high-intensity focused ultrasound (HIFU) treatment | |
JP6298449B2 (ja) | 超音波接触流動体 | |
RU2360700C2 (ru) | Дисперсный активатор для высокоинтенсивной фокусированной ультразвуковой терапии и его применение | |
RU2388492C2 (ru) | Фторуглеродный эмульсионный активатор для высокоинтенсивной фокусированной ультразвуковой терапии и его применение | |
Mancini et al. | Assessment of a modified acoustic lens for electromagnetic shock wave lithotripters in a swine model | |
Goericke-Pesch et al. | Functional anatomy and ultrasound examination of the canine penis | |
Hallowell et al. | Practical guide to ocular ultrasonography in horses and farm animals | |
CN110694081A (zh) | 一种温敏自固化抑菌型医用超声耦合剂的制备方法 | |
RU2166909C1 (ru) | Способ визуализации артерий нижних конечностей методом магнитно-резонансной ангиографии | |
Singh et al. | B-MODE INTRAOCULAR ECHOMORPHOMETRY OF MURRAH BUFFALO (Bubalus bubalis) | |
RU2438594C2 (ru) | Способ определения показаний к выбору метода оперативного лечения водянки оболочек яичка у детей по данным комплексного ультразвукового исследования | |
Scholten et al. | US location of the adductor canal hiatus: morphologic study. | |
Hwang et al. | Imaging characteristics of the eyes of cinereous vulture (Aegypius monachus): morphology and comparative biometric measurement | |
MOMOSE et al. | Effect of pressure distribution of shockwaves on renal hemorrhage after extracorporeal shockwave lithotripsy: Comparison of EDAP LT-01 and Siemens Lithostar | |
Sardo et al. | Vaginoscopy to identify vaginal endometriosis | |
Jonas et al. | 3D color doppler ultrasound for postoperative monitoring of vascularized lymph node flaps | |
Murata et al. | Ganglion cysts arising from a canine stifle joint | |
Propst et al. | A preliminary investigation of four-dimensional ultrasound for evaluation of middle ear ossicles: An in vitro study | |
RU2438584C2 (ru) | Способ диагностики субклинических форм врожденных паховых грыж |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20151127 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160415 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161221 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170228 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170517 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170613 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20170816 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171215 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20180117 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180214 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180223 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6298449 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |